Sat, Apr 19, 2014, 10:37 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

johnodod 4 posts  |  Last Activity: Feb 9, 2014 12:35 PM Member since: Jun 28, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • AnGes website announces trial start date and estimates a $ 5 billion annual market if approved.

  • This is a question for the thinkers that used to gather here in mass as opposed to the current crop of yaks who have nothing to discuss.
    Which would move the stock and validate Vical the best, news that Bristol Meyer Squib is using Vaxfectin in the next generation of their cancer immunotherapies or the news that a major pharma has licensed CyMVectin to go after the universal vaccine against birth defects?

  • johnodod by johnodod Jan 22, 2014 4:20 PM Flag

    Insider buying dipped last week as we recorded records for executive team members and directors for 62 companies. Perhaps, the early week volatility scared them back to the boardroom?

    Anyway, today we highlight a company that meets a number of our favorite criteria.

    Insiders switched from selling to buying
    Cluster buying from multiple executives
    Unusually large tickets
    Previous history of "getting it right"

    Last week, four insiders at Vical Incorporated (NASDAQ:VICL) purchased 580,000 shares for a total investment of $823,600.

    [Related -Vical (VICL) Licenses Vaxfectin Adjuvant For Use In Malaria Vaccines To Cyvax]

    Vical researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.

    The Company has three active independent clinical and preclinical development programs in the areas of infectious disease and cancer, including a fully enrolled Phase III clinical trial using its Allovectin immunotherapeutic in patients with metastatic melanoma; a completed preclinical program, with an allowed investigational new drug application, using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent cytomegalovirus, infection before and during pregnancy, and a preclinical program with therapeutic and prophylactic vaccines for herpes simplex virus type II formulated with its Vaxfectin adjuvant.

    [Related -Stocks Jump As Fed Acts To Spur Growth; Equinix (EQIX) Surges]

    All four have a remarkably similar Vical history of selling or buying for $0.01 per share. Last week's activity was the first time that any of the quartet – or any other team members for that matter – purchased VICL shares. All the other activity was selling or acquiring shares for a penny.

    Although there were four buyers, we are going to focus on the biggest. Chief Executive Officer, President, Acting Chief Financial Officer and Director, Mr. Vijay B. Samant stepped up and bought 330,000 shares at $1.42 for a total sales price of $468,600. That's close to half of his annual pay of $921,000. Would you put half your pre-tax income into any stock idea without having intimate knowledge of the inner workings and prospects?

    Prior to last week, we counted 12 Samant Vical sales and one non-open market purchase of 84,600 shares at a penny (the rich getting richer). That's why his January purchase stands out. Depositing some cash into VICL is in direct contrast to the ATM, cash withdrawal role the stock has played for the CEO.

    At the end of 2013, the company was at various phase 1 and 2 studies with the FDA. Based on insider transaction rules, we would not expect to hear much in the way of news until the late spring/early summer at the earliest. However, that doesn't mean that our quarter of buyers isn't privy to results and data on the trials to date.

    With the quartet's history of cashing out, the recent cluster of buying is a matter of connecting the dots. The change of heart has to be taken seriously.

  • johnodod johnodod Jan 19, 2014 1:42 PM Flag

    The big disappointment is the inept management team and Board of Directors that isn't focused on wealth creation for shareholders. Vical needs to make a CyMVectin deal or a Vaxfectin deal that produces some value. They should also open up about where the Herpes tests will be conducted so as to build credibility for their future programs. A-7 shredded Vijay and Vical credibility. EVERYTHING they do should be devoted to restoration of credibility as that is what will cause the stock to be valued based on potential. We are punished by bad management that hasn't faced any consequence.

1.20-0.03(-2.44%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT